1,1-Difluoroethane Hydrocarbon Cardiomyopathy

Kristen N Brown; Kyle Gronbeck; Ayesha Azmeen; Aleem Siddique; Ronald Zolty; James N Sullivan

doi:10.1016/j.jaccas.2022.101716

1,1-Difluoroethane Hydrocarbon Cardiomyopathy

JACC Case Rep. 2022 Dec 23:7:101716. doi: 10.1016/j.jaccas.2022.101716. eCollection 2023 Feb 1.

Authors

Kristen N Brown¹, Kyle Gronbeck², Ayesha Azmeen¹, Aleem Siddique³, Ronald Zolty¹, James N Sullivan⁴

Affiliations

¹ Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
² Department of Emergency Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
³ Division of Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, Nebraska.
⁴ Department of Anesthesiology, University of Nebraska Medical Center, Omaha, Nebraska.

Abstract

1,1-Difluoroethane (DFE) cardiomyopathy results from the direct inhalation of toxic halogenated hydrocarbons. We present a case series of acute DFE cardiomyopathy illustrating the typical presentation of severe DFE cardiomyopathy along with a detailed description of its mechanism of injury. (Level of Difficulty: Advanced.).

Keywords: 1,1-difluoroethane hydrocarbon; DFE, 1,1-difluoroethane; ECMO, extracorporeal membrane oxygenation; EF, ejection fraction; huffing; nonischemic cardiomyopathy; toxic cardiomyopathy.

Publication types

Case Reports